Tonix Pharmaceuticals (NASDAQ:TNXP) Stock In Serious under Pressure: Now What?
Investors of Tonix Pharmaceuticals (NASDAQ:TNXP) investors are not in the best state this week with devastating interim analysis from a late-stage clinical trial likely to fail, the stock price has plummeted below $1. The firm’s late-stage programs infamously aim at hard conditions like post-traumatic stress disorder and Alzheimer’s disease, the firm is quite weak. Yet, daring investors may be looking at positive signs in the downturn. The company on July…